|
|
- 2018
膀胱内注射肉毒素治疗膀胱过度活动症的研究进展
|
Abstract:
| [1] | Cohen BL, Barboglio P, Rodriguez D, et al. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units[J]. Neurourol Urodyn, 2009, 28(3): 205-208. |
| [2] | Sahai A, Kalsi V, Khan MS, et al. Techniques for the intradetrusor administration of botulinum toxin[J]. BJU Int, 2006, 97(4): 675-678. |
| [3] | Hegele A, Frohme C, Varga Z, et al. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance[J]. Urol Int, 2011, 87(4): 439-444. |
| [4] | Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection[J]. J Urol, 2008, 180(1): 217-222. |
| [5] | Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics[J]. Urology, 2005, 66(1): 94-98. |
| [6] | Bauer RM, Gratzke C, Roosen A, et al. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome[J]. Urol Int, 2011, 86(1): 68-72. |
| [7] | Denys P, le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study[J]. Eur Urol, 2012, 61(3): 520-529. |
| [8] | Lucioni A, Rapp DE, Gong EM, et al. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection[J]. Can J Urol, 2006, 13(5): 3291-3295. |
| [9] | Alloussi SH, Lang C, Eichel R, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction(NBD)and idiopathic detrusor overactivity(IDO)refractory to drug treatment[J]. World J Urol, 2012, 30(3): 367-373. |
| [10] | Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction[J]. Eur Urol, 2005, 48(6): 984-990. |
| [11] | Dowson C, Watkins J, Khan MS, et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates[J]. Eur Urol, 2012, 61(4): 834-839. |
| [12] | Game X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity[J]. BJU Int, 2011, 107(11): 1786-1792. |
| [13] | Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology(EAU)Guidelines on Neuro-Urology[J]. Eur Urol, 2016, 69(2): 324-333. |
| [14] | Makovey I, Davis T, Guralnick ML, et al. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability[J]. Neurourol Urodyn, 2011, 30(8): 1538-1540. |
| [15] | Lie KY, Wong MY, Ng LG. Botulinum toxin a for idiopathic detrusor overactivity[J]. Ann Acad Med Singapore, 2010, 39(9): 714-715. |
| [16] | Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder(non-neurogenic)in adults: AUA/SUFU guideline amendment[J]. J Urol, 2015, 193(5): 1572-1580. |
| [17] | Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review[J]. Int Urogynecol J, 2017, 28(6): 805-816. |
| [18] | Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics[J]. J Urol, 2006, 176(1): 177-185. |
| [19] | Knippschild S, Frohme C, Olbert P, et al. Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy[J]. Urologe A, 2012, 51(3): 379-383. |
| [20] | 付伟金, 莫曾南. A型肉毒杆菌毒素治疗膀胱过度活动症研究进展[J]. 临床泌尿外科杂志, 2006(3): 234-237. |
| [21] | Ravindra P, Jackson BL, Parkinson RJ. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA(Botox((R)))or abobotulinumtoxinA(Dysport((R)))make a difference?[J]. BJU Int, 2013, 112(1): 94-99. |
| [22] | Jabs C, Carleton E. Efficacy of botulinum toxin a intradetrusor injections for non-neurogenic urinary urge incontinence: a randomized double-blind controlled trial[J]. J Obstet Gynaecol Can, 2013, 35(1): 53-60. |
| [23] | Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women(the RELAX study)[J]. Eur Urol, 2012, 62(3): 507-514. |
| [24] | Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder[J]. Urol Ann, 2011, 3(2): 66-70. |
| [25] | Chapple CR. Finding the correct starting dose for onabotulinumtoxinA[J]. Eur Urol, 2012, 61(3): 530-532. |
| [26] | Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial[J]. J Urol, 2010, 184(6): 2416-2422. |
| [27] | Manecksha RP, Cullen IM, Ahmad S, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity[J]. Eur Urol, 2012, 61(5): 928-935. |
| [28] | Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics[J]. Neurourol Urodyn, 2011, 30(7): 1242-1248. |
| [29] | Krhut J, Samal V, Nemec D, et al. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study[J]. Spinal Cord, 2012, 50(12): 904-907. |
| [30] | Okamura K, Nojiri Y, Ameda K, et al. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes[J]. Int J Urol, 2011, 18(6): 483-487. |
| [31] | Granese R, Adile G, Gugliotta G, et al. Botox((R))for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection[J]. Arch Gynecol Obstet, 2012, 286(4): 923-929. |
| [32] | Mohee A, Khan A, Harris N, et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder(OAB)[J]. BJU Int, 2013, 111(1): 106-113. |
| [33] | Veeratterapillay R, Harding C, Teo L, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity[J]. Int J Urol, 2014, 21(2): 175-178. |
| [34] | Abeywickrama L, Arunkalaivanan A, Quinlan M. Repeated botulinum toxin type A(Dysport)injections for women with intractable detrusor overactivity: a prospective outcome study[J]. Int Urogynecol J, 2014, 25(5): 601-605. |
| [35] | Sahai A, Khan MS, le Gall N, et al. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder[J]. Urology, 2008, 71(3): 455-459. |
| [36] | King AB, Rapp DE. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity[J]. Can J Urol, 2011, 18(2): 5657-5659. |
| [37] | 那彦群, 孙光, 叶章群, 等. 2014版中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2013: 628. |
| [38] | Osman NI, Chapple CR. Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches[J]. Arab J Urol, 2013, 11(4): 313-318. |
| [39] | Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome[J]. Indian J Urol, 2013, 29(1): 2-11. |
| [40] | Seth J, Khan MS, Dasgupta P, et al. Botulinum toxin-what urologic uses does the data support?[J]. Curr Urol Rep, 2013, 14(3): 227-234. |
| [41] | Chapple C, Sievert KD, Macdiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial[J]. Eur Urol, 2013, 64(2): 249-256. |
| [42] | Schulte-Baukloh H, Bigalke H, Heine G, et al. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection[J]. Urology, 2007, 69(3): 513-575. |
| [43] | Marte A, Borrelli M, Sabatino MD, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children[J]. Eur J Pediatr Surg, 2010, 20(3): 153-157. |
| [44] | Lawrence JM, Lukacz ES, Liu IL, et al. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study[J]. Diabetes Care, 2007, 30(10): 2536-2541. |
| [45] | Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity[J]. Neurourol Urodyn, 2014, 33(8): 1235-1239. |
| [46] | Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity[J]. J Urol, 2013, 189(5): 1804-1810. |
